NCT02489500 2018-09-10
VelRand
Boston Medical Center
Phase 3 Terminated
Clinical Trials
6 trialsNCT00064337 2018-08-09
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
SWOG Cancer Research Network
Phase 2 Completed
NCT00681044 2017-04-28
HD Melphalan and SCT in Patients With IGDD or LCDD
Boston Medical Center
Phase 2 Terminated
NCT00790647 2017-02-06
Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Boston Medical Center
Phase 2 Completed
NCT00075608 2017-01-27
2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis
Boston Medical Center
Phase 2 Terminated
NCT00477971 2016-05-17
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Mayo Clinic
Phase 3 Completed